These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24687511)

  • 1. Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei.
    Jensen RH; Justesen US; Rewes A; Perlin DS; Arendrup MC
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3550-2. PubMed ID: 24687511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired echinocandin resistance in a Candida krusei blood isolate confirmed by mutations in the fks1 gene.
    Prigitano A; Esposito MC; Cogliati M; Pitzurra L; Santamaria C; Tortorano AM
    New Microbiol; 2014 Apr; 37(2):237-40. PubMed ID: 24858652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of L701 M mutation in the FKS1 gene of echinocandin-susceptible Candida krusei isolates.
    Lallitto F; Prigitano A; Mangione F; Piralla A; Tamarozzi F; Marone P; Cavanna C
    Diagn Microbiol Infect Dis; 2018 Dec; 92(4):311-314. PubMed ID: 30131237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.
    Axner-Elings M; Botero-Kleiven S; Jensen RH; Arendrup MC
    J Clin Microbiol; 2011 Jul; 49(7):2516-21. PubMed ID: 21543574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.
    Castanheira M; Woosley LN; Diekema DJ; Messer SA; Jones RN; Pfaller MA
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2655-9. PubMed ID: 20368396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.
    Desnos-Ollivier M; Bretagne S; Raoux D; Hoinard D; Dromer F; Dannaoui E;
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3092-8. PubMed ID: 18591282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
    Shields RK; Nguyen MH; Press EG; Kwa AL; Cheng S; Du C; Clancy CJ
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4862-9. PubMed ID: 22751546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
    Alexander BD; Johnson MD; Pfeiffer CD; Jiménez-Ortigosa C; Catania J; Booker R; Castanheira M; Messer SA; Perlin DS; Pfaller MA
    Clin Infect Dis; 2013 Jun; 56(12):1724-32. PubMed ID: 23487382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris.
    Kordalewska M; Lee A; Park S; Berrio I; Chowdhary A; Zhao Y; Perlin DS
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632013
    [No Abstract]   [Full Text] [Related]  

  • 10. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
    Garcia-Effron G; Katiyar SK; Park S; Edlind TD; Perlin DS
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2305-12. PubMed ID: 18443110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.
    Zimbeck AJ; Iqbal N; Ahlquist AM; Farley MM; Harrison LH; Chiller T; Lockhart SR
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5042-7. PubMed ID: 20837754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
    Pfaller MA; Diekema DJ; Andes D; Arendrup MC; Brown SD; Lockhart SR; Motyl M; Perlin DS;
    Drug Resist Updat; 2011 Jun; 14(3):164-76. PubMed ID: 21353623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positions and numbers of FKS mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment.
    Lackner M; Tscherner M; Schaller M; Kuchler K; Mair C; Sartori B; Istel F; Arendrup MC; Lass-Flörl C
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3626-35. PubMed ID: 24733467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breakthrough invasive candidiasis in patients on micafungin.
    Pfeiffer CD; Garcia-Effron G; Zaas AK; Perfect JR; Perlin DS; Alexander BD
    J Clin Microbiol; 2010 Jul; 48(7):2373-80. PubMed ID: 20421445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
    Park S; Kelly R; Kahn JN; Robles J; Hsu MJ; Register E; Li W; Vyas V; Fan H; Abruzzo G; Flattery A; Gill C; Chrebet G; Parent SA; Kurtz M; Teppler H; Douglas CM; Perlin DS
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3264-73. PubMed ID: 16048935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis.
    Jensen RH; Johansen HK; Arendrup MC
    Antimicrob Agents Chemother; 2013 Jan; 57(1):614-7. PubMed ID: 23089761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.
    Cleary JD; Garcia-Effron G; Chapman SW; Perlin DS
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2263-5. PubMed ID: 18378714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid development of Candida krusei echinocandin resistance during caspofungin therapy.
    Forastiero A; Garcia-Gil V; Rivero-Menendez O; Garcia-Rubio R; Monteiro MC; Alastruey-Izquierdo A; Jordan R; Agorio I; Mellado E
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6975-82. PubMed ID: 26324281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates.
    Arendrup MC; Jørgensen KM; Hare RK; Cuenca-Estrella M; Zaragoza O
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31285230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.